High Throughput Screening-Based Identification of Measles Virus Probes
High Throughput Screening-Based Identification of Measles Virus Probes
批准号:
7293434
负责人:
Richard K. Plemper
金额:
$2.5万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
已结题
起止时间:
2007-06-01 至 2008-05-31
关键词:
AccountingAfricaAnimal ModelAntiviral AgentsAsiaAttenuated Live Virus VaccineBackBiochemicalBiologicalBiological AssayBiologyCanine Distemper VirusCase ManagementCase StudyCellsCessation of lifeChimeric ProteinsClassClassificationClinicalCollaborationsComplexCotton RatsDataDevelopmentDisease OutbreaksDockingDoseEnsureEuropeEvaluationExerciseFamilyFutureGene ExpressionGenerationsGenetic TranscriptionGenomeGoalsGreen Fluorescent ProteinsHousingHumanHuman Parainfluenza Virus 2In VitroIndividualInhibitory Concentration 50LibrariesLife Cycle StagesManualsMeaslesMeasles virusMembrane FusionMonitorMorbidity - disease rateParamyxovirusPharmaceutical PreparationsPilot ProjectsPolymeraseQuantitative Structure-Activity RelationshipRangeRecombinantsReporterReproducibilityResearchResistanceRouteScreening procedureSpecificityStagingTestingTherapeuticToxic effectVaccinesViralVirusVirus DiseasesVirus Replicationbaseclinically relevantconceptcytotoxiccytotoxicityfollow-uphigh throughput screeningin vivoindexinginhibitor/antagonistinsightmembermortalitynovelnovel therapeuticspathogenpharmacophorepre-clinicalprogramsreceptor bindingrespiratoryresponsesmall moleculesuccessviral RNA
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Measles virus (MV), a member of the paramyxovirus family, remains one of the ten most lethal human pathogens despite the existence of a live-attenuated vaccine. The virus is endemic in Africa, Asia and parts of Europe, and cases are reported annually in the US. No therapy is available for management of severe cases of measles or rapid control of local outbreaks. It is therefore the long-term objective of this project to develop novel inhibitors of MV. Towards this goal multiple assays have been established in pilot studies and a research plan with three specific aims will be implemented. The first specific aim provides a robust assay to the MLSCN for hit identification through high throughput screening (HTS). A cell-based automated assay has been established that employs a fluorescent MV reporter stably expressing green fluorescent protein as additional transcription unit. Assay evaluation has revealed favorable z'-values of 0.8 and a pilot screen of a 34,000 compound in- house library at Emory has yielded amongst others a promising new inhibitor class, providing proof-of-concept for the approach. The second specific aim backs up the automated hit discovery with three independent manual assays that quantify suppression of virus-induced cytopathicity and reduction of virus yields in the presence of compound, and determine inherent compound cytotoxicity. Collectively, these assays allow hit confirmation, calculation of active concentrations, and assessment of compound selectivity. The third specific aim determines the target specificity of potent hits towards MV in comparison with other members of the paramyxovirus family, and subjects selected candidates to an initial characterization of the mechanism of antiviral activity. Candidate probes with high biologic activity towards MV will be subjected to testing against closely related canine distemper virus and distantly related human parainfluenza virus type 2. In individual assays, the effect of selected compounds on receptor binding, membrane fusion, and viral gene expression and genome replication will then be examined. Combined, this screening exercise will enable us to identify the most promising small molecule probes that merit future biochemical characterization of docking modes, further in vitro optimization through generation of quantitative structure-activity relationships and pharmacophore extraction, and in vivo toxicity and efficacy testing using the cotton rat small animal model for MV infection. Collectively, paramyxoviruses are responsible for significant morbidity and mortality worldwide. Measles virus (MV) alone, a member of this virus family, accounts for approximately 500,000 deaths annually, placing it among the most lethal human pathogens despite the existence of a vaccine. This is partially due to the exceptionally high infectivity of MV and the fact that no therapy is available for management of severe cases of measles or rapid control of local outbreaks. The high-throughput screening-based identification of novel biological probes that interfere with MV replication and spread, and the further development of applicable drugs based on these probes is therefore the ultimate objective of this project.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Project 1 – Development of Orally Bioavailable beta-CoV Inhibitors
-
批准号:10513942
-
项目类别:
-
资助金额:$413.93万
-
财政年份:2022
-
负责人:Richard K. Plemper
-
依托单位:
Polymerase Inhibitors of Respiratory Syncytial Virus
-
批准号:10666509
-
项目类别:
-
资助金额:$68.94万
-
财政年份:2020
-
负责人:Richard K. Plemper
-
依托单位:
Polymerase Inhibitors of Respiratory Syncytial Virus
-
批准号:10425285
-
项目类别:
-
资助金额:$68.94万
-
财政年份:2020
-
负责人:Richard K. Plemper
-
依托单位:
Polymerase Inhibitors of Respiratory Syncytial Virus
-
批准号:10034283
-
项目类别:
-
资助金额:$80.7万
-
财政年份:2020
-
负责人:Richard K. Plemper
-
依托单位:
Polymerase Inhibitors of Respiratory Syncytial Virus
-
批准号:10199980
-
项目类别:
-
资助金额:$78.08万
-
财政年份:2020
-
负责人:Richard K. Plemper
-
依托单位:
Development of a Broad-Spectrum Inhibitor against Seasonal and Highly-Pathogenic Influenza Viruses
-
批准号:10544324
-
项目类别:
-
资助金额:$91.32万
-
财政年份:2019
-
负责人:Richard K. Plemper
-
依托单位:
Development of a Broad-Spectrum Inhibitor against Seasonal and Highly-Pathogenic Influenza Viruses
-
批准号:10080034
-
项目类别:
-
资助金额:$97.96万
-
财政年份:2019
-
负责人:Richard K. Plemper
-
依托单位:
Drug discovery against lyssaviruses by high thoughput screening
-
批准号:9218526
-
项目类别:
-
资助金额:$39.84万
-
财政年份:2016
-
负责人:Richard K. Plemper
-
依托单位:
Identification and Hit-to-Lead Development of Influenza A Virus Inhibitors
-
批准号:8955538
-
项目类别:
-
资助金额:$23.69万
-
财政年份:2015
-
负责人:Richard K. Plemper
-
依托单位:
Novel Therapeutics against Respiratory Syncytial Virus Infection
-
批准号:8662435
-
项目类别:
-
资助金额:$62.29万
-
财政年份:2014
-
负责人:Richard K. Plemper
-
依托单位:
Host-Directed Inhibitors of Myxovirus Replication
-
批准号:8566072
-
项目类别:
-
资助金额:$17.12万
-
财政年份:2012
-
负责人:Richard K. Plemper
-
依托单位:
Cryo-Electron and Biochemical Anaysis of Native Paramyxovirus Fusion Complexes
-
批准号:8700311
-
项目类别:
-
资助金额:$33.96万
-
财政年份:2011
-
负责人:Richard K. Plemper
-
依托单位:
Cryo-Electron and Biochemical Anaysis of Native Paramyxovirus Fusion Complexes
-
批准号:8876533
-
项目类别:
-
资助金额:$33.96万
-
财政年份:2011
-
负责人:Richard K. Plemper
-
依托单位:
Cryo-Electron and Biochemical Analysis of Native Paramyxovirus Fusion Complexes
-
批准号:8041821
-
项目类别:
-
资助金额:$35.31万
-
财政年份:2011
-
负责人:Richard K. Plemper
-
依托单位:
Cryo-Electron and Biochemical Anaysis of Native Paramyxovirus Fusion Complexes
-
批准号:8488398
-
项目类别:
-
资助金额:$33.05万
-
财政年份:2011
-
负责人:Richard K. Plemper
-
依托单位:
Cryo-Electron and Biochemical Analysis of Native Paramyxovirus Fusion Complexes
-
批准号:8291987
-
项目类别:
-
资助金额:$24.04万
-
财政年份:2011
-
负责人:Richard K. Plemper
-
依托单位:
Cryo-Electron and Biochemical Anaysis of Native Paramyxovirus Fusion Complexes
-
批准号:8595851
-
项目类别:
-
资助金额:$14.5万
-
财政年份:2011
-
负责人:Richard K. Plemper
-
依托单位:
Cryo-Electron and Biochemical Analysis of Native Paramyxovirus Fusion Complexes
-
批准号:8090559
-
项目类别:
-
资助金额:$37.99万
-
财政年份:2010
-
负责人:Richard K. Plemper
-
依托单位:
Counteracting Resistance through Host-Directed Myxovirus Inhibitors
-
批准号:7774286
-
项目类别:
-
资助金额:$23.25万
-
财政年份:2010
-
负责人:Richard K. Plemper
-
依托单位:
Counteracting Resistance through Host-Directed Myxovirus Inhibitors
-
批准号:8067978
-
项目类别:
-
资助金额:$19.18万
-
财政年份:2010
-
负责人:Richard K. Plemper
-
依托单位:
海外基金